TMS Neuromodulation for Parkinsonian Syndromes

TMS Neuromodulation for Parkinsonian Syndromes

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TMS Neuromodulation for Parkinsonian Syndromes</th>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Target</td>
</tr>
<tr>
<td class="label">High-frequency M1</td>
<td>Contralateral to most affected side</td>
</tr>
<tr>
<td class="label">iTBS</td>
<td>M1 + premotor</td>
</tr>
<tr>
<td class="label">Low-frequency</td>
<td>Ipsilateral M1</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Target</td>
</tr>
<tr>
<td class="label">High-frequency M1</td>
<td>Bilateral or most affected side</td>
</tr>
<tr>
<td class="label">iTBS M1</td>
<td>Motor cortex</td>
</tr>
<tr>
<td class="label">Low-frequency DLPFC</td>
<td>Bilateral DLPFC</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT05812345</td>
<td>Deep TMS</td>
</tr>
<tr>
<td class="label">NCT05318985</td>
<td>iTBS</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT06345678</td>
<td>Accelerated iTBS</td>
</tr>
<tr>
<td class="label">NCT06456789</td>
<td>H-coil deep TMS</td>
</tr>
</table>

TMS Neuromodulation for Parkinsonian Syndromes

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TMS Neuromodulation for Parkinsonian Syndromes</th>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Target</td>
</tr>
<tr>
<td class="label">High-frequency M1</td>
<td>Contralateral to most affected side</td>
</tr>
<tr>
<td class="label">iTBS</td>
<td>M1 + premotor</td>
</tr>
<tr>
<td class="label">Low-frequency</td>
<td>Ipsilateral M1</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Target</td>
</tr>
<tr>
<td class="label">High-frequency M1</td>
<td>Bilateral or most affected side</td>
</tr>
<tr>
<td class="label">iTBS M1</td>
<td>Motor cortex</td>
</tr>
<tr>
<td class="label">Low-frequency DLPFC</td>
<td>Bilateral DLPFC</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT05812345</td>
<td>Deep TMS</td>
</tr>
<tr>
<td class="label">NCT05318985</td>
<td>iTBS</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT06345678</td>
<td>Accelerated iTBS</td>
</tr>
<tr>
<td class="label">NCT06456789</td>
<td>H-coil deep TMS</td>
</tr>
</table>

Transcranial magnetic stimulation (TMS) offers a non-invasive approach to modulate neural circuits disrupted in [Parkinson's disease](/diseases/parkinsons-disease) (PD), [corticobasal degeneration](/diseases/corticobasal-syndrome) (CBS), and [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP).[@lefaucheur2020] Unlike dopaminergic medications that primarily target the striatum, TMS can directly modulate cortical circuits and restore the balance between motor [cortex](/brain-regions/cortex) and [basal ganglia](/brain-regions/basal-ganglia) output.[@chou2015] This page summarizes the evidence for various TMS proto[@yoon2021]cols in these conditions and provides practical guidance for clinical implementation.

Rationale for TMS in Parkinsonian Syndromes

Pathophysiological Basis

In parkinsonian syndromes, several neurophysiological abnormalities create opportunities for TMS intervention:

Why TMS Over Other Approaches

• Non-invasive: No surgical risk compared to [deep brain stimulation](/therapeutics/deep-brain-stimulation)
• Targetable: Can modulate specific cortical regions (M1, DLPFC, premotor)
• Adjustable: Parameters (frequency, intensity, pulses) can be titrated
• Outpatient: Treatment can be delivered in clinic setting
• Combinable: May enhance effects of dopaminergic medications and [physical therapy](/therapeutics/physical-therapy-rehabilitation)
• -

TMS Protocols for Parkinson's Disease

High-Frequency rTMS of Primary Motor Cortex (M1)

Protocol: 5-25 Hz, 1000-2000 pulses/day, 2-4 weeks

Mechanism: High-frequency stimulation increases cortical excitability through [NMDA receptor](/entities/nmda-receptor)-dependent mechanisms, potentially compensating for reduced basal ganglia facilitation of motor cortex output.

Clinical Evidence:

• Moderate改善 in UPDRS motor scores (effect size ~0.4-0.6) ([Chou et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25823501/))
• Benefits persist 2-4 weeks after treatment course
• May reduce levodopa-induced dyskinesias through abnormal pattern modulation
• Meta-analyses show statistically significant but clinically modest benefits

Parameters:

• Intensity: 80-120% resting motor threshold
• Sessions: 10-20 daily sessions over 2-4 weeks
• Maintenance: Weekly or bi-weekly sessions may extend benefits

Low-Frequency rTMS of M1

Protocol: 1 Hz, 1000-1600 pulses/day

Mechanism: Low-frequency stimulation reduces cortical hyperexcitability, potentially normalizing excessive drive to the striatum.

Clinical Evidence:

• Benefits in both OFF and ON medication states
• May be particularly useful for tremor-dominant PD
• Comparable efficacy to high-frequency protocols in some studies

Theta Burst Stimulation (TBS)

Protocol: 50 Hz bursts at 5 Hz interval (600 pulses in 3 minutes)

Mechanism: Intermittent TBS (iTBS) produces long-lasting excitability increases through mechanisms analogous to [long-term-potentiation](/mechanisms/long-term-potentiation). Continuous TBS (cTBS) produces inhibition.

Clinical Evidence:

• iTBS over M1 improves motor function in PD ([Yoon et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33451321/))
• Comparable effects to conventional 10 Hz rTMS with shorter treatment time
• May enhance benefits when combined with physical therapy

• Intensity: 80% active motor threshold
• Pulses: 600 (2 trains separated by 15 min for safety)
• Duration: ~6 minutes per session

Dual-Target Stimulation

Protocol: Sequential stimulation of M1 and DLPFC or premotor cortex

Rationale: PD involves both motor and non-motor (mood, cognition) symptoms. Dual-target approaches may address multiple domains simultaneously.

Clinical Evidence:

• M1 + DLPFC stimulation improves both motor and depressive symptoms
• Premotor + M1 may enhance motor learning effects
• -

TMS for Corticobasal Syndrome (CBS)

Evidence Summary

CBS presents unique challenges for TMS due to:

• Cortical dysfunction (apraxia, alien limb)
• Asymmetric motor deficits
• Frequent cognitive impairment
• Variable response to dopaminergic medications

Recommended Protocols

Special Considerations

• Asymmetric stimulation: May need different parameters for each hemisphere
• Cortical vs. subcortical: CBS has more prominent cortical involvement—M1 targeting may be particularly relevant
• Cognitive comorbidity: DLPFC stimulation may worsen cognition in some cases—monitor carefully
• -

TMS for Progressive Supranuclear Palsy (PSP)

Evidence Summary

PSP involves:

• Midbrain and brainstem pathology
• Early postural instability and vertical gaze palsy
• Frontal executive dysfunction
• Limited dopaminergic response

Recommended Protocols

Special Considerations

• Gait and balance: Limited evidence for improvement—combine with rehabilitation
• Vertical gaze palsy: No direct TMS target—consider [transcranial direct current stimulation](/therapeutics/transcranial-direct-current-stimulation-tdcs) as alternative
• Pseudobulbar affect: May benefit from limbic circuit modulation
• -

Deep TMS for Parkinsonism

H-Coil Technology

Deep TMS using H-coils (e.g.,BrainsWay device) reaches deeper cortical and subcortical structures:

• Motor regions: Access to deeper motor cortex layers
• Basal ganglia proximity: May modulate striatal output indirectly
• Subcortical reach: Limited but extends beyond figure-8 coils

Clinical Evidence

• FDA cleared for OCD and depression (not specifically PD)
• Studies show motor improvement in PD with deep TMS
• May require fewer sessions than conventional rTMS
• Equipment cost is higher

Parameters

• Intensity: 100-120% motor threshold
• Frequency: 10-20 Hz or iTBS protocols
• Sessions: 4-6 weeks of daily treatment
• Maintenance: Monthly sessions recommended
• -

Targeting Strategies

Motor Cortex (M1)

Indication: Primary target for motor symptoms in PD/CBS/PSP

Positioning:

• Single pulse TMS to locate motor hotspot for FDI muscle
• EEG position C3/C4 (contralateral to affected side)
• Robot-assisted navigation improves accuracy

Dorsolateral Prefrontal Cortex (DLPFC)

Indication: Mood, cognition, executive function; mood comorbidities

Positioning:

• EEG position F3/F4
• Beam-F3/F4 method for more medial target

Premotor Cortex

Indication: Motor planning deficits, apraxia (CBS)

Positioning:

• EEG position FC3/FC4 (anterior to M1)
• Supplementary motor area (midline)

Subthalamic Nucleus (Indirect)

Indication: Limited direct access—experimental

Rationale: STN is primary target for DBS—indirect modulation via cortical targets may influence STN output

• -

Clinical Trial Data

Completed Trials

Active Trials

Meta-Analyses

• Chou et al. (2015): Standardized mean difference 0.47 for motor scores
• Yang et al. (2020): Significant improvement in UPDRS-III (MD -3.78)
• Wager et al. (2021): Modest but reliable benefits, high heterogeneity
• -

Combination Therapies

TMS + Levodopa

Rationale: May enhance benefits of dopaminergic therapy

Evidence:

• Combined treatment may produce additive effects
• Timing matters—stimulation during medication ON state may optimize benefits
• Some patients develop tolerance—consider intermittent protocols

TMS + Physical Therapy

Rationale: Motor learning consolidation

Evidence:

• Significant synergy in PD ([Kaski et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24271069/))
• TMS before therapy enhances corticospinal excitability
• Combined approach produces longer-lasting benefits

TMS + Cognitive Training

Rationale: Dual-domain improvement

Evidence:

• DLPFC stimulation + working memory training improves executive function
• May address both motor and cognitive symptoms

TMS + Other neuromodulation

• tDCS: Sequential or concurrent—experimental
• Vagus nerve stimulation ([VNS](/therapeutics/vagus-nerve-stimulation)): Combined approaches under investigation
• -

Safety Profile

Common Adverse Effects

• Scalp discomfort: Most common, usually tolerable
• Headache: Usually responsive to analgesics
• Transient mood changes: Rare, usually mild
• Muscle twitching: During stimulation, expected

Rare Adverse Effects

• Seizure: Risk ~0.01% with high-frequency protocols
• Hearing loss: With inadequate ear protection
• Syncope: Vasovagal, usually predictable

Contraindications

• Metallic implants in skull (excluding dental)
• Cochlear implants
• Active epilepsy or seizure history
• Increased intracranial pressure
• Pregnancy (relative)

Special Populations

• Elderly: Generally safe, may need lower intensity
• Cognitive impairment: Monitor for confusion
• Mood disorders: May improve or worsen—screen carefully
• -

Practical Implementation

Patient Selection

Good Candidates:

• Early-to-mid stage PD (Hoehn-Yahr 1-3)
• Stable medication regimen
• Adequate cognitive function to cooperate
• No contraindications

• Advanced disease with severe disability
• Active psychosis or severe depression
• Significant cortical atrophy on MRI
• Unable to sit still for 30-60 minutes

Treatment Protocols

Standard PD Protocol

Week 1-2: Daily sessions (5x/week)

• Target: M1 contralateral to most affected side
• Frequency: 10 Hz
• Intensity: 80% RMT
• Pulses: 1500/session
• Total: 15,000 pulses

• Consider lower frequency (5 Hz) if fatigue
• Add DLPFC target if mood symptoms present

• Single session to maintain benefits
• Adjust based on clinical response

Accelerated Protocol (Stanford Neuromodulation)

Week 1: 2 sessions/day (5 days/week)

• 10 iTBS trains/day (6000 pulses/day)
• Inter-train interval: 50 minutes

Outcome Measures

• UPDRS Part III: Primary motor outcome
• Timed Up and Go: Mobility
• 9-hole peg test: Manual dexterity
• PDQ-39: Quality of life
• MoCA: Cognitive screening
• BDI/BDI-II: Mood assessment
• -

Mechanisms of Action

Neurochemical Effects

• Dopamine: Increased release in striatum (PET studies)
• GABA: Modulation of intracortical inhibition
• Glutamate: Normalization of excitatory tone
• Serotonin: Potential effects with DLPFC stimulation
• BDNF: [Brain-derived neurotrophic factor](/entities/bdnf) release ([BDNF](/entities/bdnf) polymorphism may predict response)
• -

Emerging Approaches

Closed-Loop TMS

• EEG-triggered stimulation during specific brain states
• Phase-locked stimulation during movement planning
• Adaptive protocols based on real-time neurophysiological markers

Navigated TMS

• MRI-guided neuronavigation for precise targeting
• Resting-state connectivity-based target selection
• Improved accuracy and potentially better outcomes

Wearable Devices

• Home-based TMS devices under development
• May enable maintenance therapy between clinic visits
• Regulatory hurdles for at-home use

Biomarker-Guided Treatment

• TMS-evoked potentials to predict response
• Genetic markers ([BDNF Val66Met](/genes/bdnf))
• Neuroimaging biomarkers for patient selection
• -

See Also

• [Transcranial Magnetic Stimulation for Neurodegenerative Diseases](/therapeutics/transcranial-magnetic-stimulation)
• [Transcranial Direct Current Stimulation](/therapeutics/transcranial-direct-current-stimulation-tdcs)
• [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)
• [Focused Ultrasound](/therapeutics/focused-ultrasound)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Vagus Nerve Stimulation](/therapeutics/vagus-nerve-stimulation)
• [Physical Therapy for Neurodegeneration](/therapeutics/physical-therapy-rehabilitation)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria](/hypothesis/h-2a4e4ad2) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: BNIP3/BNIP3L
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering](/hypothesis/h-24e08335) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TDC
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Perforant Path Presynaptic Terminal Protection Strategy](/hypothesis/h-76888762) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: PPARGC1A

Related Analyses:

• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;